Chronic hepatitis C is a leading cause of hepatocellular carcinoma worldwide. Interferon therapy decreases the incidence of hepatocellular carcinoma in patients with chronic hepatitis C. Prevention of chronic hepatitis C-related HCC is one of the most important issues in current hepatology. We previously reported that male gender and high-titer of HCV-RNA were predictive factors for the development of hepatocellular carcinoma in the anti-HCV positive group. Clinical efforts of eradicating or reducing the viral load may reduce the risk for hepatocellular carcinoma.
